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ABSTRACT: A ferrocene containing ortho-aminoanilide, N1-(2-aminophenyl)-N8-ferrocenyloctanediamide, 2b (Pojamide) dis-
played nanomolar potency vs. HDAC3. Compared to RGFP966, a potent and selective HDAC3 inhibitor, Pojamide displayed 
superior activity in HCT116 colorectal cancer cell invasion assays; however, TCH106 and Romidepsin, potent HDAC1 inhibitors, 
outperformed Pojamide in cellular proliferation and colony formation assays. Together, these data suggest that HDAC 1 & 3 inhi-
bition is desirable to achieve maximum anti-cancer benefits. Additionally, we explored Pojamide-induced redox-pharmacology. 
Indeed, treating HCT116 cells with Pojamide, SNP (sodium nitroprusside) and glutathione (GSH) led to greatly enhanced cytotox-
icity and DNA damage attributed to activation to an Fe(III) species. 
Introduction 
Histone deacetylases (HDACs) are key targets in cancer and 
neurodegeneration1. Their overexpression leads to increased 
deacetylated lysine/arginine levels and a condensed chromatin 
state resulting in transcriptional silencing. Clinically useful 
HDAC inhibitors (HDACis) include SAHA2 (Fig. 1) and Ro-
midepsin3, which trigger growth arrest and apoptosis via histone 
hyperacetylation by pan-inhibition principally of Class I and II 
HDACs and other targets (e.g. p53). 
Our increased knowledge of HDAC biology has emphasised 
the need for isoform-selective histone deacetylase inhibitors 
(HDACis)4. Selective inhibitors of HDAC3, (e.g. the benzamides 
TCH106 and RGFP966) (Fig. 1)5-6, are particularly attractive in 
CNS applications7 and cancer8. However, recent studies using 
HDAC3-overexpressing HCT116 cells show that silencing indi-
vidual HDACs (1-3) through RNAi is insufficient to achieve simi-
lar levels of growth arrest and apoptosis induced by generic 
HDACis such as Trichostatin A9. It is therefore likely that the 
inhibition of specific combinations of HDAC isoforms, HDACs 
1-3 in particular, may help to achieve the full benefits of HDAC 
inhibition in colorectal carcinomas and possibly other cancer 
cells. 
 
Figure 1. SAHA, and known HDACis. 
  
Results and Discussion 
Transition metal-based anticancer agents are interesting due to 
their novel ligand exchange and redox chemistry, the ability of a 
heavy metal atom to facilitate phasing in protein x-ray crystallog-
raphy and the availability of geometries and oxidation states 
unachievable with carbon-based therapeutics10-13. Ferrocene-based 
JAHAs and other metal-based analogues, many containing a hy-
droxamic acid zinc-binding group (ZBG), are effective HDACis 
with good activity vs. Class I HDACs14-25. Guided by docking 
studies of a standard “cap-linker-ZBG” arrangement, we wished 
to extend the chemistry of JAHAs to ortho-anilide analogues, 
anticipating that this may lead to HDAC3-selectivity and alleviate 
toxicity issues documented for hydroxamate ZBGs26. Hence, 
compounds 1a and 2a were readily made by standard coupling 
reactions and were characterised in the solid state by x-ray crys-
tallography (Figure 2)27. 
Figure 2. Ferrocene-based HDACis and precursors. 
 
To explore the binding modes of 1b and 2b (Pojamide) in 
HDAC3 we performed docking studies using the structure of 
HDAC3 bound to co-repressor and inositol tetraphosphate (Figure 
3A,B)29. We found that Pojamide bound to the zinc active site 
forming hydrogen bonds between the N-H of the amide and the 
carbonyl of Asp93, the benzamide amide N-H and the carbonyl of 
Gly143, the aniline NH2 and the nitrogen of His134, and the car-
bonyl of Asp170 as well as the characteristic benzamide-zinc 
interaction.  
The docked structure of 1b is docked slightly shifted from 
Pojamide. It forms hydrogen bonds with Asp93 and Gly143. 
However, the substitution of the 6- carbon aliphatic chain for a 4-
carbon chain results in a rotation of the benzamide group leading 
to a loss of key interactions, namely, hydrogen bonding with 
His134 and Asp170 as well as forcing zinc coordination from the 
benzamide aniline to the amide carbonyl (Figure 3A,B). Compari-
son of the active sites of HDAC3 and 8 reveals that ferrocenyl 
substitution for the archetypal aryl cap in HDAC inhibitors in 
Pojamide clashes with Tyr100 and Lys33 in HDAC8; assuming a 
similar binding mode to that of Pojamide in HDAC3. Thus it is 
assumed that ferrocenyl substitution in Pojamide and 1b is re-
sponsible for HDAC3 selectivity (Figure 3C). 
In addition to structural evidence supporting selective HDAC3-
binding, we confirmed Pojamide’s cell permeation and HDAC3-
specificity using Xenopus laevis embryos (2-cell to stage 14) as a 
model system for deacetylase activity. Xenopus laevis embryos 
were incubated with 1b and Pojamide in order to test their bioa-
vailability and JAHA, a broad HDAC inhibitor, was used as a 
positive control30. As expected Pojamide and 1b, which have 
some selectivity towards HDAC3 (vide infra), did not affect -
tubulin acetylation, whereas JAHA increased acetylation of -
tubulin (Figure S1A). Acetylated H4K12 (H4K12ac) has, howev-
er, been shown to be a target of HDAC3 and was expected to 
increase if these HDAC3is were able to function in the whole 
organism31. Compound 1b gave no sign of affecting H4K12 acet-
ylation levels unlike Pojamide, which demonstrated a concentra-
tion-dependent accumulation of H4K12ac (Figure S1B). In three 
separate experiments the level of H4K12ac, as detected by west-
ern blotting, increased in developing embryos treated with Poja-
mide; however, embryo development was severely affected and 
many died (as low as 10% survival rates). For this reason, it was 
impossible to obtain a clear concentration-dependency for Poja-
mide, nonetheless we conclude that Pojamide is highly likely to 
be cell-permeable as an HDAC3 inhibitor, but that compound 1b 
is not. 
      
      
      
       
Figure 3. A,B) Docking poses of 1b and Pojamide in HDAC3 
(PDB code: 4A69). Top docking poses of 1b (teal, A) and Poja-
mide (slate, B) in HDAC3. C) Superposition of the active sites of 
HDAC3 (gray) and HDAC828 (PDB code: 1T69, green) showing 
key residues overlaid with Pojamide top docking pose in 
HDAC3. Color Scheme: Hydrogen bonds shown in green dashed 
lines, π-π interactions shown in orange dashed lines. 
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 Next, we tested Pojamide on a panel of HDACs vs. 1b, SAHA 
and HDAC3is (Table 1)32. Indeed both 1b and Pojamide dis-
played ca. 11- and 22-fold selectivity respectively towards 
HDAC3 over HDACs 1/2 and significantly greater selectivity 
over HDACs 4-8. Pojamide’s profile was on par with other or-
tho-anilide (benzamide) inhibitors, being most similar to that of 
TCH106, yet was outperformed by RGFP966 with respect to 
HDAC3-selectivity. Only SAHA displayed activity vs. HDAC8 
(Table 1). 
With in vitro validation of the anti-HDAC3 activity of these 
ferrocene-analogues, we sought to explore their inhibitory activity 
in HDAC3-overexpressing cervical and colorectal cancer cell 
lines. HeLa, HT-29 and HCT116 cells are tumor-forming cell 
lines that have been used previously as model systems to charac-
terise HDACis9,33-35. We confirm in this study that compared to 
hTERT immortalised Retinal Pigment Epithelium (RPE) cells – 
cells with a longer lifespan, but incapable of forming tumors36 – 
the malignant cancer cell lines HeLa, HT-29 and HCT116 all 
showed significantly elevated HDAC3 expression levels (Figure 
4). 
 
Figure 4. Western blot analysis of HDAC3 and α-Tubulin (Tub) 
in Retinal Pigment Epithelium (RPE), HeLa, HT-29 and HCT116 
cells.  
Table 1. Biochemical evaluation of HDAC isoforms 1 – 8. 
IC50 (M) 
HDAC SAHA[a] 1b 2b[a] RGFP966 TCH106[b] 
1 0.006 ± 0.001  8.94 1.10 ± 0.14 0.61 0.39 
2 0.016 ± 0.001 13.79 1.3 ± 0.4 0.58 1.2 
3 0.008 ± 0.001 0.606 0.09 ± 0.02  0.015 0.05     
4 19 ± 1 >30 >30 >30 >30     
5 9.7 ± 0.1 >30 >30 >30 >30     
6 0.030 ± 0.001  >30 >30 >30 >30     
7 >30 >30 >30 >30 >30     
8 0.36 ± 0.10 >30 >30 >30 >30 
[a]Profiling done in duplicate, n=8. All others n=4; [b] Slow, tight-binding inhibi-
tor, with inverted IC50 and Ki values, causes IC50 value to drop over longer pre-
incubation periods.6 The IC50 value was defined as the amount of compound 
that caused 50% reduction in HDAC activity in comparison with DMSO-treated 
control and was calculated using GraphPad Prism version 6 software. 
Based on these data, this small panel of cell lines was treated 
with increasing concentrations of 1b, Pojamide and the control 
HDACis RGFP966 and TCH106. Despite RGFP966 showing 
6.5-fold greater potency than Pojamide in blocking HDAC3 ac-
tivity (Table 1), we found that RGFP966 and Pojamide are equi-
potent at inhibiting HCT116 cellular proliferation, displaying 
GC50 values of 8.9 and 8.6 μM respectively (Figure 5A, Table 2). 
RPE cells on the other hand were as sensitive to Pojamide as 
HCT116 cells, but were not inhibited by RGFP966 (Figure 5B, 
Table 2). TCH106 displayed superior potency against all cell 
lines with GC50 values ranging from 1 – 2 M and completely 
blocked colony formation at 10 M in HCT116 colony formation 
assays compared to 75 and 60% inhibition of colony formation by 
Pojamide and RGFP966 respectively (Figures 5A-E, S2A-C). 
Interestingly, TCH106 is 1.6- and 2.8-fold more potent toward 
HDAC1 inhibition than RGFP966 and Pojamide respectively 
(Table 1) and proliferating RPE cells have been shown to overex-
press HDACs 1, 2 and 537, suggesting that HDAC1 inhibition is in 
part responsible for the anti-proliferative effects of Pojamide and 
TCH106 in these cell lines. In fact, cellular proliferation and col-
ony formation assays using Romidepsin, a potent and exquisitely 
selective HDAC1/2 inhibitor (reported IC50 values of 36 and 47 
nM respectively38), revealed a GC50 value of 0.52 ± 0.02 nM and 
near complete inhibition of colony formation at 0.5 nM; clearly 
the most potent anti-proliferative HDACi tested in this study 
(Figures 5F, S3A,B). HeLa and HT-29 cells were only mildly 
inhibited by Pojamide and RGFP966 showing maximal growth 
inhibition of ~40 and 30% at 10 μM respectively, and in all cases 
compound 1b was ineffective at inhibiting cellular proliferation 
(Figure 5A-D). This result was mirrored in Xenopus laevis em-
bryo development assays, whereby Pojamide caused a concentra-
tion-dependent increase in acetylated H4K12 levels and 1b did 
not (Figure S1). 
      
Figure 5. A-D) (A) HCT116, (B) RPE, (C) HeLa and (D) HT-29 CellTiter-Blue proliferation assays. E) HCT116 colony formation assays; 
% Colony formation (normalised to DMSO control) was quantitated manually and the average ± S.D. was plotted. F) Inhibitory activity of 
Romidepsin on HCT116 cellular proliferation. G-I) HCT116 cellular invasion assays in the presence of (G) RGFP966, (H) TCH106 and 
(I) Pojamide. 
To establish the anti-invasive properties of Pojamide against 
known HDACis, we investigated the effects of RGFP966, 
TCH106 and Pojamide on HCT116 cellular invasion. In this 
assay, we decided to test compounds at 1x and 0.1x of their GC50 
value determined using the HCT116 cellular proliferation assay. 
At the lowest concentrations tested, only Pojamide demonstrated 
robust inhibition of invasion, with about 70% inhibitory activity; 
however, at the 1x concentrations both RGFP966 and Pojamide, 
exhibiting ca. 40 and 11-fold selectivity for HDAC3 inhibition 
respectively compared to HDAC1 (Table 1), inhibited invasion by 
about 90% compared to 70% for TCH106, which showed only 7-
fold selectivity for HDAC3 vs. HDAC1 inhibition (Figure 5G-I). 
Based on these data and taking into consideration the activity of 
these compounds in the cellular proliferation assay, we conclude 
that HDAC isoform synergystic effects can be exploited using 
HDAC1- and HDAC3-selective HDACis; proliferation being 
attenuated more so by HDAC1, and possibly HDAC2, inhibition 
and invasion blocked more robustly through HDAC3 inhibition. 
Table 2. Cellular characterization of HDACis 
GC50 (M) or (nM)[b] 
Cell Line 2b TCH106 RFP966 Romidepsin 1b 
RPE 9.0 ± 0.7 ≈ 1 na nd na 
HCT116 8.6 ± 1.2 2.2 ± 0.2 8.9 ± 0.7 0.52 ± 0.02[b] na 
HeLa na 1.5 ± 0.2 na  nd na     
HT-29 na ≈ 1 na nd na     
[a]The GC50 value was defined as the amount of compound that caused 
50% reduction in cellular proliferation in comparison with DMSO-treated 
control and was calculated using GraphPad Prism version 6 software; na 
= not applicable and nd = not determined.  
 
Pojamide appears more efficacious in preventing HCT116 cel-
lular invasion, particularly at lower concentrations (i.e. 1 M). In 
addition, we wanted to explore the possibility that engaging a 
different oxidation state of the iron atom in the ferrocene moiety 
might offer a unique advantage at targeting cancer cells. Seminal 
studies with Ehrlich ascites tumor (EAT) cells and HPB (human 
leukemic T lymphocytes) showed that incubation with ferroceni-
um salts (e.g. Fe(III)Cp2PF6) inhibited tumor growth, whereas 
their ferrocene counterparts were ineffective. Indeed, ferroceni-
um’s toxicity involves the generation of OH radicals and the 
rapid induction of DNA-damage; repeated later in MCF7 and 
MCF10A cells39-40. 
In order to take advantage of ferrocenium cytotoxicity, we gen-
erated the ferrocenium species 3b (Fe(III)-Poj) through standard 
means by reacting Pojamide with nitrosonium (NO+) tetra-
fluoroborate (Scheme 1), which was confirmed by cyclic voltam-
metry41 (Figure S4). Hence, we hypothesised that intracellular 
generation of NO+ in the presence of Pojamide might also lead to 
Fe(III)-Poj in cells. 
Scheme 1. Synthetic ferrocenium Pojamides. 
 
It has previously been reported that sodium nitroprusside (SNP) 
leads to intracellular NO+ release42, yet studies in neuronal PC12 
cells have shown that SNP alone triggers apoptosis at concentra-
tions greater than 30 M42. To develop a cell-based assay utilising 
SNP as an NO+ donor, we conducted cytotoxicity studies using 
the colony formation assay (Figures S5A). At 25 M SNP, just 
shy of the concentration that triggers apoptosis in PC12 cells, 
HCT116 colony formation is reduced by about 30%; however, 
addition of 500 M GSH completely eliminated SNP cytotoxicity 
(Figure S5A,B). GSH is a free radical scavenger, detoxifies H2O2 
in a glutathione peroxidase-1 dependent manner43 and its cytopro-
tective effects were demonstrated in our assay at concentrations of 
50 and 500 M, whereby GSH treatments, in the presence of 
 SNP, enhanced colony formation by about 4 and 10% respectively 
(Figure S5A,B). The reaction of SNP with GSH to form innocu-
ous NO may further reduce SNP cytotoxicity44. 
 
 
Figure 6. A-C) Western analysis of pH2AX and -tubulin (Tub) in HCT116 cells treated for 3 d with (A) RGFP966, (B) Pojamde and 
(C) Pojamide + SNP/GSH. D) The pH2AX/Tub ratio was determined via densitometry and the average ratio normalised to DMSO control 
was plotted as the mean ± S.D. E) Western analysis of pH2AX and -tubulin (Tub) in HCT116 cells treated for 6 d as indicated above. 
F,G) NAD+ fold-induction (F), total NAD+/NADH (F) and reactive oxygen species (ROS) (G) levels normalised to the DMSO control; 
the average (n=10) was plotted ± S.D. The t-test statistical module of Prism 6.0 was used to determine p-values (ns (not statistically signif-
icant): P > 0.05; *: P ≤ 0.05; **: P ≤ 0.01; ***: P ≤ 0.001). 
After identifying the optimal conditions for SNP/GSH treat-
ment, we treated HCT116 cells with increasing concentrations of 
inhibitor in the presence and absence of SNP/GSH. The genera-
tion of Fe(III)-Poj was monitored by blotting for the DNA-
damage marker phospho-H2AX (pH2AX)45 (Figure 6A-D). 
Without SNP/GSH, increasing concentrations of RGFP966 and 
Pojamide reduced pH2AX levels, but addition of SNP/GSH to 
cells treated with Pojamide led to an initial decrease in pH2AX, 
with recurrence of the DNA-damage marker at concentrations 
greater than 2 M (Figure 6A-D). In a longer time-course (6 d) 
with 4 M inhibitor (± SNP/GSH), only the Pojamide/SNP/GSH 
combination led to significant DNA-damage nearly tantamount to 
the levels of DNA-damage caused by cisplatin (4 M) (Figure 
6E). 
To further support that our SNP/GSH treatment in the presence 
of Pojamide leads to production of Fe(III)-Poj, we assessed the 
levels of NAD+ in cells using the NAD/NADH-Glo Assay.  Early 
studies on the one-electron transfer from NADH to ferrocenium 
oxidants such as Fe(III)Cp2PF6 demonstrated that ferrocenium 
salts can successfully oxidise NADH to NAD+ at physiologic pH 
in a phosphate buffer in vitro46. To recapitulate this conversion in 
cells, we treated HCT116 cells with DMSO/SNP/GSH and 2.5 
M Pojamide with and without SNP/GSH. For each condition, 
total NAD+/NADH levels remained the same, but Pojamide in 
the presence of SNP/GSH led to an increase in NAD+ levels; 
similar to those obtained with synthetic Fe(III)-Poj. In contrast, 
Pojamide treatment alone decreased NAD+ levels (Figure 6F).  
In order to correlate this increase in NAD+ with oxidative 
stress, reactive oxygen species (ROS) levels were determined in 
HCT116 cells treated with Pojamide, the non-transition metal-
based HDAC3i RGFP966, and other transition metal-based com-
pounds JAHA and ruthenocene. Indeed, without SNP/GSH, both 
ferrocene-ligands Pojamide and JAHA caused an induction in 
ROS; an effect documented with other ferrocene-ligands such as 
ferrocifens and aminoferrocene prodrugs, which produce quinone 
methides, and in the latter case, ferrocenium catalysts for ROS 
production, in the absence of SNP47,48. DMSO, RGFP966 and 
ruthenocene were assayed and showed no ROS induction without 
SNP/GSH. In the presence of SNP/GSH, ROS levels increased by 
2.5-fold with and without RGFP966 and, interestingly, all other 
conditions with SNP/GSH, Pojamide, JAHA and ruthenocene, 
led to greater ROS levels with Pojamide displaying the most 
significant increase, 3.3-fold, despite co-treatment with excess 
GSH (Figure 6G). 
 
 
Figure 7. A) HCT116 colony formation assays; % Colony formation 
(B) (normalised to DMSO control) was quantitated manually and the 
 average ± S.D. was plotted. The t-test statistical module of Prism 6.0 was used to determine p-values (ns (not statistically significant): P > 
0.05; *: P ≤ 0.05; **: P ≤ 0.01; ***: P ≤ 0.001). 
Figure 8. Model for the enhanced redox-triggered cytotoxicity of 
Pojamide. 
With cellular validation of Fe(III)-Poj generation, we tested 
our system in the HCT116 colony formation assay (Figures 
7A,B). Pojamide alone caused a significant decrease in colony 
formation, which was enhanced by addition of SNP/GSH; 27 and 
53% inhibition respectively. At 4 M, RGFP966, with and with-
out SNP/GSH, displayed a 10 – 15% reduction in colony for-
mation; however, like Pojamide, both ferrocenium salts were less 
effective without SNP/GSH. In combination with SNP/GSH, 
Fe(III)-Poj and Fe(III)Cp2PF6 caused a slight, about 10%, re-
duction in colony formation (Figure 7A,B). Interestingly, colonies 
resulting from treatment with ferrocenium salts and SNP/GSH 
were larger, but overall fewer colonies formed; a result similar to 
RGFP966 treatment. Although the cytotoxicity of ferrocenium 
salts is well documented, their activity is ~100-fold reduced com-
pared to Pojamide39, perhaps due to limited membrane permea-
bility, and explains their meagre inhibitory activities at the 4 and 
20 M concentrations tested. 
 
Conclusions 
In summary, the SNP/GSH combination treatment is an ideal 
system for increasing the intracellular ferrocenium concentration 
from a Pojamide precursor. Also, when Fe(III)-Poj is reduced 
back to the Fe(II) species, it would be available to act upon 
HDACs. Due to having two separate modes of action, one which 
is SNP/GSH-dependent, Pojamide is advantageous compared to 
other similarly potent HDACis: its cytotoxicity is enhanced by its 
facile conversion to the cytotoxic Fe(III) species in cells, whilst 
the reduced species inhibits cellular invasion through potently 
targeting HDAC3 and proliferation, to a lesser extent, due to its 
low micromolar HDAC1 inhibitory activity (Figure 8). Lastly, co-
treatments of intravenous SNP injection along with Pojamide 
administration might offer a highly efficacious strategy for man-
aging some colon carcinomas; a strategy that might have broader, 
generalizable applications when used with pharmacologically 
distinct Fe(II)Cp2-containing drugs (e.g. aminoferrocenes, ferro-
cifens, ferroquines).47-50 Current studies are looking at ruthenium-
based HDACis and will be reported in due course.  
Experimental. 
Solvents and reagents were purchased from commercial sup-
pliers and were used without purification. Ferrrocenylamine 
was purchased from TCI, UK, and used as such. All reactions 
were performed in a fume hood. NMR spectra were recorded 
on Varian 500 MHz or 400 MHz spectrometers and chemical 
shifts are reported in ppm, usually referenced to TMS as an 
internal standard. LCMS were performed by Shimadzu 
LCMS-2020 equipped with a Gemini® 5µm C18 110Å col-
umn and percentage purities were ran over 30 minutes in wa-
ter/acetonitrile with 0.1% formic acid (5 min at 5%, 5%-95% 
over 20 min, 5 min at 95%) with the UV detector at 254 nm. 
High-resolution mass spectrometry (HRMS) was performed 
by the EPSRC National Mass Spectrometry Facility, Universi-
ty of Swansea. Elemental analyses were conducted by Stephen 
Boyer (London Metropolitan University). FT-IR were record-
ed on a PerkinElmer Spectrum Version 10.03.06.  
Tert-butyl-2-(6-oxo-6-phenylamino)hexanamido)ferrocenyl 
carbamate 1a.  
6-Oxo-6-(ferrocenylamino)hexanoic acid14 (493.6 mg, 1.5 
mmol, 1 equiv.) and N-Boc-o-phenylenediamine (343.4 mg, 
1.65 mmol, 1.1 equiv.) were dissolved in dichloromethane (18 
mL). To this triethylamine (1.17 mL, 9 mmol) was added and 
the mixture was cooled in an ice bath. Next, propane phos-
phonic acid anhydride (T3P) (50% solution in DMF, 1.38 mL, 
1.1 mmol) was added and the reaction mixture was allowed to 
warm up to room temperature overnight. Then the mixture was 
poured into a saturated solution of K2CO3, stirred for 30 min. 
and extracted into CH2Cl2 (DCM). The organic layer was dried 
(MgSO4), filtered and evaporated in vacuo. The residue was 
purified by trituration with DCM to give an orange solid 
(576.3 mg, 74%). Crystallization by solvent evaporation of 
DCM provided yellow crystals. 1H NMR (DMSO-d6, 500 
MHz):  = 9.44 (1H, s, NH), 9.22 (1H, s, NH), 8.31 (1H, s, 
NH), 7.53 (1H, d, J=7.8 Hz, CHAr), 7.41 (1H, d, J=7.8 Hz, 
CHAr), 7.12-7.04 (1H, m, CHAr), 7.06 (1H, d, J=7.8 Hz, 
CHAr), 4.57 (2H, s, 2CH (Cp)), 4.08 (5H, s, unsusbst. Cp), 
3.93 (2H, s, 2CH (Cp)), 2.37 (2H, d, J=8.3 Hz, CH2), 2.19 
(2H, t, J=6.1 Hz, CH2), 1.65-1.56 (4H, m, 2CH2), 1.45 (9H, s, 
3CH3). 
13C NMR (DMSO-d6, 126 MHz ):  = 171.0, 153.5, 
130.1, 125.4, 125.3, 124.3, 124.1, 96.1, 79.8, 69.2, 64.1, 61.1, 
36.2, 28.7, 28.5, 25.3. 
N1-(2-Aminophenyl)-N6-ferrocenyladipamide 1b. The pre-
vious compound, tert-butyl-2-(6-oxo-6-
(phenylamino)hexanamido)ferrocenylcarbamate, (520 mg, 
1.00 mmol, 1 equiv.) was suspended in dichloromethane (40 
mL) and MeOH (4 mL). To this mixture 4N HCl/dioxane (8 
mL) was added and the mixture was stirred at room tempera-
ture overnight. The volatiles were removed in vacuo, then sat. 
Na2CO3 (aq.) was added to the residue and the mixture was 
sonicated. The precipitate was collected by suction and 
washed on the frit with water, dried, triturated with CH2Cl2 to 
give the title compound as a brown solid (318 mg, 76%). 1H 
NMR (DMSO-d6): 9.21 (1H, s, NH), 9.09 (1H, s, NH), 7.15 
(1H, d, J=7.8 Hz, CHAr), 6.78-6.73 (1H, m, CHAr), 6.70 (1H, 
dd, J=7.8, 1.4 Hz, CHAr), 6.53 (1H, dd, J=7.8, 1.4 Hz, CHAr), 
4.80 (2H, s, NH2), 4.56 (2H, s, 2CH (Cp)), 4.08 (5H, s, un-
subst. Cp), 3.92 (2H, s, 2CH (Cp)), 2.36-2.32 (2H, m, CH2), 
2.25-2.10 (2H, m, CH2), 1.68-1.54 (4H, m, 2CH2). 
13C NMR 
(DMSO-d6, 126 MHz ):  = 171.4, 171.1, 142.3, 126.1, 125.7, 
124.1, 116.6, 116.3, 96.1, 69.2, 64.1, 61.1, 36.3, 36.1, 25.5. 
HRMS-ESI (m/z): found 420.1366, calc. for [C22H26FeN3O2]
+ 
420.1369. Anal. calcd (%) for C22H25FeN3O2: C, 63.02; H, 
6.01; N, 10.02. Found (%): C, 62.85; H, 6.05; N, 9.84. 
Tert-butyl-2-(8-oxo-8-(phenylamino)octanamido) ferro-
cenylcarbamate 2a. Methyl-8-oxo-8-
(ferrocenylamino)octanoic acid (215 mg, 0.6 mmol, 1 equiv.) 
and N-Boc-o-phenylenediamine (137.4 mg, 0.66 mmol, 1.1 
equiv.) were dissolved in dichloromethane (7.7 mL). To this 
triethylamine (0.5 mL, 3.6 mmol) was added and the mixture 
was cooled in an ice bath. Next, propane phosphonic acid an-
hydride T3P (50% solution in DMF, 0.59 mL, 0.66 mmol) was 
added and the reaction mixture was allowed to warm up to 
room temperature overnight. Then the mixture was poured 
into saturated solution of K2CO3, stirred for 30 min. and ex-
tracted into CH2Cl2. The organic layer was dried (MgSO4), 
filtered and evaporated in vacuo. The residue was purified by 
trituration with DCM to give the orange solid (233.1 mg, 
 71%). Crystallization by solvent evaporation of DCM provid-
ed yellow crystals. 1H NMR (DMSO-d6): 9.40 (1H, s, NH), 
9.15 (1H, s, NH), 8.26 (1H, s, NH), 7.54-7.48 (1H, m, CHAr), 
7.42-7.35 (1H, m, CHAr), 7.13-7.09 (1H, m, CHAr), 7.08-7.03 
(1H, m, CHAr), 4.55 (2H, s, 2CH (Cp)), 4.06 (5H, s, unsusbt. 
Cp), 3.91 (2H, s, 2CH (Cp)), 2.33 (2H, t, J=7.4 Hz, CH2), 2.14 
(2H, t, J=7.4 Hz, CH2), 1.62-1.54 (4H, m, 2CH2), 1.44 (9H, s, 
3CH3), 1.38-1.26 (4H, m, 2CH2). 
13C NMR (DMSO-d6, 126 
MHz ):  = 171.6, 171.2, 142.3, 126.1, 125.7, 124.1, 116.6, 
116.3, 96.1, 69.1, 64.1, 61.0, 39.7, 39.5, 36.4, 36.2, 29.0, 28.9, 
25.7, 25.6.  
 N1-(2-Aminophenyl)-N8-ferrocenyloctanediamide 2b 
(Pojamide) 
Tert-butyl-2-(8-oxo-8-(phenylamino)octanamido)ferrocenyl 
carbamate (136.8 mg, 0.25 mmol, 1 equiv.) was suspended in 
dichloromethane (10 mL) and MeOH (1 mL). To this mixture 
4N HCl/dioxane (2 mL) was added and the mixture was stirred 
at room temperature overnight. The volatiles were removed in 
vacuo, then sat. Na2CO3 (aq.) was added to the residue and the 
mixture was sonicated. The precipitate was collected by suc-
tion and washed on the frit with water, dried, triturated with 
CH2Cl2 to give the title compound as a brown solid (82 mg, 
73%). 1H NMR (DMSO-d6): 9.18 (1H, s, NH), 9.05 (1H, s, 
NH), 7.14 (1H, dd, J=8.0, 1.5 Hz, CHAr), 6.91-6.84 (1H, m, 
CHAr), 6.70 (1H, dd, J=8.0, 1.5 Hz, CHAr), 6.54-6.48 (1H, m, 
CHAr), 4.78 (2H, s, NH2), 4.57 (2H, t, J=1.9 Hz, 2CH (Cp)), 
4.08 (5H, s, unsubst. Cp), 3.92 (2H, t, J=1.9 Hz, 2CH (Cp)), 
2.31 (2H, t, J=7.4 Hz, CH2), 2.15 (2H, t, J=7.4 Hz, CH2), 1.68-
1.53 (4H, m, 2CH2), 1.35-1.29 (4H, m, 2CH2). 
13C NMR 
(DMSO-d6, 126 MHz):  = 171.6, 171.2, 142.3, 126.1, 125.7, 
124.1, 116.6, 116.3, 96.1, 69.1, 64.1, 61.0, 39.7, 39.5, 36.4, 
36.2, 29.0, 28.9, 25.7, 25.6. HRMS-ESI (m/z): found 
448.1675, calc. for [C24H30FeN3O2]
+ 448.1682. Anal. Calcd 
(%) for C24H29FeN3O2: C, 64.44; H, 6.53; N, 9.39. Found (%): 
C, 64.23; H, 6.60; N, 9.29. 
Tert-butyl-2-(8-oxo-8-(phenylamino)octanamido) ferroce-
niumcarbamate tetrafluoroborate, 3a. Tert-butyl-2-(8-oxo-
8-(phenylamino)octanamido)ferrocenylcarbamate (109.5 mg, 
0.2 mmol, 1 equiv.) was suspended in dry DCM (5 mL). To 
this NOBF4 (37.4 mg, 0.32 mmol, 1.6 equiv.) was added. The 
color of the solution changed from yellow to dark brown. Fil-
tration afforded the title compound as a dark brown solid (89 
mg, 70%). 19F NMR (DMSO-d6): -29.53. 11B NMR (DMSO-
d6): -2.56. C29H37BF4FeN3O4: C, 54.92; H, 5.88; N, 6.62. 
Found (%): C, 55.08; H, 5.84; N, 6.57. FTIR (cm-1): 992 (BF4
-
). 
N1-(2-Aminophenyl)-N8-ferroceniumoctanediamide tetra-
fluoroborate, 3b (Fe(III)-Poj). N1-(2-Aminophenyl)-N8-
ferrocenyloctanediamide (100 mg, 0.2 mmol, 1 equiv.) was 
suspended in dry DCM (5 mL). To this NOBF4 (37.4 mg, 0.32 
mmol, 1.6 equiv.) was added. The color of the solution 
changed from yellow to dark brown. Filtration afforded the 
title compound as a dark brown solid (78 mg, 73%). 19F NMR 
(DMSO-d6): -29.53. 11B NMR (DMSO-d6): -1.34. 
C24H29BF4FeN3O2: C, 67.12; H, 5.80; N, 9.49. Found (%): C, 
66.97; H, 5.84; N, 9.31. FTIR (cm-1): 1038 (BF4). 
Supporting Information 
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